Aims Dabigatran is largely cleared by renal excretion. Renal function is thus a major
determinant of trough dabigatran concentrations, which correlate with the risk of …

Dabigatran etexilate (dabigatran) is a direct oral thrombin inhibitor approved for the
prevention of ischemic stroke in patients with nonvalvular atrial fibrillation. Dabigatran has …

Introduction Dabigatran is effective and widely used to prevent ischemic stroke and systemic
embolism (SE) in patients with atrial fibrillation (AF). Chronic kidney disease (CKD) also has …

Background Plasma concentrations of the anticoagulant dabigatran are correlated with
clinical outcomes, and are affected by renal function, intestinal P‐glycoprotein (P‐gp) activity …

Abstract Background and Objective: Dabigatran etexilate is an oral direct thrombin inhibitor
in clinical development for the prevention and treatment of thromboembolic disorders …

Introduction Dabigatran etexilate is an oral direct thrombin inhibitor. Although routine
anticoagulation monitoring with dabigatran is not usually required, a simple and precise …

The objective of this work was to derive a dosing regimen for dabigatran in patients with
severe renal impairment by modeling and simulation. Data from a dedicated renal …

Background In clinical practice, physicians are given the choice of selecting one of two
dabigatran doses based on patient characteristics, with the lower dose typically used in …

Introduction Although dabigatran, an oral direct thrombin inhibitor, does not require routine
monitoring, high plasma concentration of dabigatran (PDC) at trough level is shown to be a …

Background Hemodialysis has been shown to be a useful method of decreasing dabigatran
plasma levels in situations that require rapid elimination of this thrombin inhibitor. However …